Drug Trial Radar · NCT07038005
A Phase I Study of SPGL008 in Subjects With Advanced Malignant Tumors
Last checked: Nov 19, 2026Latest source record: Feb 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
96
Planned (sponsor's estimate)
Start
Jul 30, 2025
Primary completion
Sep 22, 2026
Study completion Jun 8, 2027
Sponsor
- Lead sponsor
- Shenyang Sunshine Pharmaceutical Co., LTD.Industry
- Sponsor type
- Industry
- Collaborators
- Shenzhen Sciprogen Bio-pharmaceutical Co., Ltd.
- First posted
- Jun 26, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study includes two cohorts, respectively evaluating safety, tolerability and preliminary efficacy of intravenous and subcutaneous administration of SPGL008.
Conditions
- Advanced Malignant Tumors
Interventions
SPGL008Drug
Biological product
Primary outcomes
What the sponsor says the trial is designed to measure.
- Dose Limiting Toxicity (DLT)Time frame: During the first cycle. Each cycle is 21 days
- Maximum tolerated dose (MTD)Time frame: During the first cycle. Each cycle is 21 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Chongqing University Cancer Hospital
Chongqing, Chongqing Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.